Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multicenter Randomized Controlled Trial of Perioperative Chemotherapy Combined With Low-Dose Radiotherapy and Tislelizumab Versus Chemotherapy Alone in Patients With Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07408609 is registered in ClinicalTrials.gov with Jiangsu Cancer Institute & Hospital as lead sponsor.

NCT NCT07408609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07408609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multicenter Randomized Controlled Trial of Perioperative Chemotherapy Combined With Low-Dose Radiotherapy and Tislelizumab Versus Chemotherapy Alone in Patients With Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Lead sponsor
Jiangsu Cancer Institute & Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 26, 2026
Completion date
February 20, 2031
Enrollment
114 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastric or gastroesophageal junction adenocarcinoma